SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Statistics and Information Department MsS, Ministry of Health and Welfare of Japan. Vital statistics 2000, Japan. Tokyo: Health and Welfare Statistics Association, 2000.
  • 2
    Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998; 72: 141196.
  • 3
    Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24: 132138.
  • 4
    Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61: 32253229.
  • 5
    Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001; 61: 249255.
  • 6
    Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancer and malignant phenotype suppression. J Natl Cancer Inst. 2001; 93: 691699.
  • 7
    Brabender J, Usadel H, Danenberg KD, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene. 2001; 20: 35283532.
  • 8
    Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001; 61: 34193424.
  • 9
    Sobin LH, Wittekind C. TNM classification of malignant tumours. New York: Wiley-Liss, 1997.
  • 10
    Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, and Collaborators from 14 Countries. World Health Organization. International histological classification of tumors. Histological typing of lung and pleural tumors. 3rd edition. Berlin: Springer-Verlag, 1999.
  • 11
    Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93: 98219826.
  • 12
    Zochbauer-Muller S, Fong KM, Maitra A, et al. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001; 61: 35813585.
  • 13
    Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst. 2000; 92: 13031307.
  • 14
    Tsuchiya T, Tamura G, Sato K, et al. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene. 2000; 19: 36423646.
  • 15
    Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59: 793797.
  • 16
    Esteller M, Corn PG, Urena JM, et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 1998; 58: 45154518.
  • 17
    Graff JR, Herman JG, Myohanen S, et al. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem. 1997; 272: 2232222329.
  • 18
    Sato M, Mori Y, Sakurada A, et al. The H-cadherin (CDH13) gene is inactivated in human lung cancer [published erratum appears in Hum Genet. 1998;103(4):532]. Hum Genet. 1998; 103: 96101.
  • 19
    Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 20
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 21
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 22
    Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 1996; 85: 1726.
  • 23
    Fong KM, Biesterveld EJ, Virmani A, et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 1997; 57: 22562267.
  • 24
    Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000; 60: 19491960.
  • 25
    Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998; 58: 50325037.
  • 26
    Tomizawa Y, Nakajima T, Kohno T, et al. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res. 1998; 58: 54785483.
  • 27
    Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer. 2000; 82: 11911197.
  • 28
    Tseng JE, Kemp BL, Khuri FR, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. 1999; 59: 47984803.
  • 29
    Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001; 61: 86598663.
  • 30
    Kremmidiotis G, Baker E, Crawford J, et al. Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. Genomics. 1998; 49: 467471.
  • 31
    Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 2001; 61: 45564560.
  • 32
    Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000; 25: 315319.
  • 33
    Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 2003; 103: 153160.
  • 34
    Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 1993; 2: 425434.
  • 35
    Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000; 60: 43664371.
  • 36
    Virmani AK, Rathi A, Sathyanarayana UG, et al. Promoter methylation and inactivation of the adenomatous polyposis coli (APC) gene in breast and lung carcinomas. Clin Cancer Res. 2001; 7: 19982004.